Suppr超能文献

华法林治疗患者在急诊科就诊时的出血并发症

Bleeding Complications in Warfarin-Treated Patients Admitted to the Emergency Department.

作者信息

Ozturk Mustafa, Ipekci Afsin, Kiyak Sevil Kusku, Akdeniz Yonca Sinem, Aydin Yavuz, Ikizceli Ibrahim, Sogut Ozgur

机构信息

Department of Emergency Medicine, University of Health Sciences, Haseki Training and Research Hospital, Istanbul, Turkey.

Department of Emergency Medicine, University of Istanbul Cerrahpasa, Istanbul, Turkey.

出版信息

J Clin Med Res. 2019 Feb;11(2):106-113. doi: 10.14740/jocmr3669. Epub 2019 Jan 5.

Abstract

BACKGROUND

Increased use of warfarin for the treatment and prophylaxis of many diseases has increased the frequency of adverse events. Emergency departments (EDs) are the first places where early interventions for bleeding and other complaints related to warfarin use are performed. This study assessed the characteristics of patients receiving warfarin and the risk factors for bleeding complication among those admitted to the ED.

METHODS

Patients admitted to the ED for any reason other than trauma during a 1-year period were retrospectively reviewed. The study population consisted of 96 patients who had received warfarin and had an international normalized ratio (INR) ≥ 3. Patient demographics and medical history were recorded.

RESULTS

The mean age of the patients (female, 52.1%) was 64.9 ± 14.5 years. Fatigue was the most common presenting complaint (61%). At least one major and/or minor bleeding event had occurred in 32 (33.3%) of the patients. Patients with (n = 32) and without (n = 64) bleeding complications did not significantly differ with respect to age, sex, reason for warfarin initiation, duration of warfarin use, concomitant diseases, and concurrent medications. There were also no significant differences in the distribution of patient admissions in terms of season at presentation, INR level, and weekly warfarin dose.

CONCLUSIONS

While the parameters evaluated in this study did not significantly differ among warfarin-treated patients, they may nonetheless pose a risk of bleeding. Further large-scale and long-term studies that take into account biological variation are required to precisely identify the risk factors for bleeding.

摘要

背景

华法林在多种疾病的治疗和预防中的使用增加,导致不良事件的发生频率上升。急诊科是对与华法林使用相关的出血及其他症状进行早期干预的首要场所。本研究评估了急诊科收治的接受华法林治疗患者的特征以及出血并发症的危险因素。

方法

回顾性分析在1年期间因非创伤原因入住急诊科的患者。研究人群包括96例接受华法林治疗且国际标准化比值(INR)≥3的患者。记录患者的人口统计学资料和病史。

结果

患者的平均年龄为64.9±14.5岁,女性占52.1%。疲劳是最常见的就诊主诉(61%)。32例(33.3%)患者至少发生过一次严重和/或轻微出血事件。有出血并发症(n = 32)和无出血并发症(n = 64)的患者在年龄、性别、开始使用华法林的原因、华法林使用时长、合并疾病及同时服用的药物方面无显著差异。在就诊季节、INR水平和每周华法林剂量方面,患者入院分布也无显著差异。

结论

虽然本研究评估的参数在接受华法林治疗的患者中无显著差异,但这些参数仍可能存在出血风险。需要开展进一步考虑生物学变异的大规模长期研究,以准确识别出血的危险因素。

相似文献

9
Effect of oral corticosteroids on chronic warfarin therapy.口服皮质类固醇对慢性华法林治疗的影响。
Ann Pharmacother. 2006 Dec;40(12):2101-6. doi: 10.1345/aph.1H418. Epub 2006 Nov 21.

引用本文的文献

2
Are We Overusing Coagulation Studies in the Emergency Department?我们在急诊科过度使用凝血功能检查了吗?
Emerg Med Int. 2024 Apr 23;2024:8694183. doi: 10.1155/2024/8694183. eCollection 2024.
3
Oral Anticoagulation in Patients with Chronic Liver Disease.慢性肝脏疾病患者的口服抗凝治疗。
Medicina (Kaunas). 2023 Feb 12;59(2):346. doi: 10.3390/medicina59020346.
4
Evaluation of adverse drug reaction in patients warfarin therapy.华法林治疗患者的药物不良反应评估。
J Adv Pharm Technol Res. 2022 Oct-Dec;13(4):291-295. doi: 10.4103/japtr.japtr_439_22. Epub 2022 Oct 10.
7
Is there a circannual variation in the anticoagulation control of warfarin?华法林抗凝控制是否存在年周期变化?
Eur J Hosp Pharm. 2023 Jan;30(1):41-45. doi: 10.1136/ejhpharm-2021-002793. Epub 2021 Apr 26.

本文引用的文献

5
Emergency department management of patients on warfarin therapy.华法林治疗患者的急诊科管理。
Ann Emerg Med. 2011 Aug;58(2):192-9. doi: 10.1016/j.annemergmed.2011.01.018. Epub 2011 Apr 8.
6
Anticoagulant-associated intracerebral hemorrhage.抗凝相关脑出血。
Semin Neurol. 2010 Nov;30(5):565-72. doi: 10.1055/s-0030-1268866. Epub 2011 Jan 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验